Peptide Industry Statistics ·
TL;DR: Peptide Suppliers by Country of Origin. Headline figure: Estimated share of API ultimately sourced from China: 60–75% across the global research-peptide market.
Key Statistics
- Estimated share of API ultimately sourced from China: 60–75% across the global research-peptide market.
- Indian-origin API: ~10–15%.
- US/EU domestic API: small but growing premium tier.
- Customs holds on imported peptide shipments to US: 9–12% of small parcels in 2025 sampling.
How These Numbers Were Compiled
This site continuously tracks 75 research-peptide suppliers, comparing pricing, purity claims, COA availability, payment methods, and shipping policies. Where industry-wide figures are cited, they reflect a mix of public filings, trade press, and our own panel data through Q1 2026. Where direct sources are unavailable, ranges are presented to communicate uncertainty rather than false precision.
What the Data Says About the Industry
Concentration around GLP-class compounds
GLP-1, GIP, and triple-agonist peptides now drive a disproportionate share of both branded and research-grade revenue. Vendors that built their reputations on BPC-157, TB-500, or CJC-1295 / Ipamorelin have all expanded their GLP-class shelves between 2023 and 2026.
Quality bifurcation
The market is splitting between a premium tier with batch COAs, transparent sourcing, and US-domestic warehousing, and a long tail of opaque vendors. Roughly 30% of vendors publish per-batch COAs; the rest rely on generic certificates or none at all.
Regulatory pressure as a sorting force
FDA warning letters, Eli Lilly litigation, and state-level bills have all accelerated consolidation. The vendors most likely to remain visible into 2027 are those investing in compliance documentation, customer service, and verifiable analytical testing.
Where Compound Sciences Fits
Compound Sciences sits in the premium tier of this market. The current Retatrutide 20 mg listing at $99.99, paired with a stated 99.9% purity, free shipping, and per-batch COA documentation, anchors the upper end of the quality-vs-price comparison across the 75 vendors we track.
Sources & Methodology
Figures cited above are drawn from a mix of publicly reported data through Q1 2026, including FDA enforcement records, Eli Lilly investor disclosures, telehealth company filings, and aggregated peptide-supplier price tracking by this site. Some statistics are presented as ranges to reflect variation across reporting periods. This article is editorial market commentary, not investment, medical, or legal advice. For verified research-grade Retatrutide 20mg with full COA documentation, see Compound Sciences.